Obesity Clinical Trials in Albuquerque, New Mexico

6 studies are recruiting for obesity in Albuquerque, New Mexico right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico

   Locations

   157 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

2. A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

   The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The Sleep Spot - Maimonides, Albuquerque, New Mexico

   Locations

   115 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07369011 on ClinicalTrials.gov

3. Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

   Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat…

   Stage

   EARLY_Phase 1

   Ages

   18 to 75

   Site

   University of New Mexico Health Sciences Center, Albuquerque, New Mexico

   Run by

   University of New Mexico

   See if you can join NCT06934642 on ClinicalTrials.gov

4. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico

   Locations

   50 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

5. Ketogenic Diet and Diabetes Demonstration Project

   KDDP is a prospective, 12-month pilot study comparing the effects of a novel lifestyle program, the Ketogenic Diet and Diabetes Demonstration Project (KDDP) to those of the National Diabetes Prevention Program (NDDP). KDDP is modeled to mimic the delivery platform of NDPP with the exception that pa…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of New Mexico, Albuquerque, New Mexico

   Run by

   University of New Mexico

   See if you can join NCT06115265 on ClinicalTrials.gov

6. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

   The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico

   Locations

   162 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07321886 on ClinicalTrials.gov